Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue (2010 - 2026)

Biocryst Pharmaceuticals' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (changed N/A YoY) and the FY2022 annual result came in at $1.2 million, down 13.86% from the prior year.
• Current Deferred Revenue was $5.4 million for Q1 2026 at Biocryst Pharmaceuticals, up from $522000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $5.4 million in Q1 2026 and bottomed at $522000.0 in Q3 2023.
• A 3-year average of $1.8 million and a median of $1.5 million in 2022 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 263.21% — and 2023, when it tumbled 66.41%.
• Biocryst Pharmaceuticals' Current Deferred Revenue stood at $1.2 million in 2022, then plunged by 57.35% to $522000.0 in 2023, then surged by 936.21% to $5.4 million in 2026.
• Business Quant data shows BCRX's Current Deferred Revenue at $5.4 million in Q1 2026, $522000.0 in Q3 2023, and $1.8 million in Q2 2023.